Rentschler Biopharma Promotes Patrick Cushing as VP Operations for U.S. Subsidiary

Rentschler Biopharma SE, a prominent contract development and manufacturing organization (CDMO), has appointed Patrick Cushing, Ph.D. as the Vice President Operations for its U.S. subsidiary. Effective from May 1, 2024, Dr. Cushing will manage operational processes at Milford’s facility and report to Christiane Bardroff, the Chief Operating Officer.

Christiane Bardroff stated that Dr. Cushing's new role supports Rentschler’s commitment to high-quality services and fits their vision of advancing medicine. The role was created to enhance the operational efficiency at Milford’s facility, which has recently augmented its manufacturing capacity.

Dr. Cushing expressed enthusiasm about his new role and the opportunity it presents to strengthen synergies within the global organization. He also emphasized the potential impact on patient’s lives through improved medicine development and delivery.

Prior to this promotion, Dr. Cushing served as Senior Director of Manufacturing Operations since joining the company in 2021. His vast experience includes leadership roles in contract research and manufacturing sectors, specializing in drug discovery and process development for complex biologics.

The expansion at the Milford site includes a new manufacturing line featuring four new 2,000 L bioreactors, significantly increasing the company’s global cGMP capacity. This facility will focus on commercial production of complex molecules for international markets.